Real time people search
Who is

Jacques Bienaime

MA, Hyde Park, 175 Clare Ave, 2136

Pictures(14)

 
 
 
No data available
 
Find hidden profiles and photos for Jacques Bienaime across MySpace, Facebook and 40+ networks.

Weblinks(4)

Jean-Jacques Bienaimé - BioMarin Pharmaceutical
Jean-Jacques Bienaime. Chief Executive Officer. Mr. Bienaimé joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors, ...
Jean Jacques Bienaime | LinkedIn
View Jean Jacques Bienaime's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Jean Jacques ...
Jean-Jacques Bienaimé: Executive Profile & Biography ...
Mr. Jean-Jacques Bienaime has been Chief Executive Officer of Biomarin Pharmaceutical Inc. since May 2005. Mr. Bienaime served as the Chief Executive  ...
Fireside Chat With Jean-Jacques Bienaimé, Chief Executive Officer ...
Fireside Chat With Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin. Type: ... Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and  ...
No data available

Blogs(0)

No data available

Books(0)

No data available

Articles(0)

Documents(4)

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the 32nd ...
Jan 7, 2014 ... Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a company update at the 32 nd. Annual J.P. Morgan. Healthcare ...
A TT'OZNEYS - Googleapis.com
Sept. 21, 1965. J. BIENAIME. 3,207,340. EARTHMOVING AND HOISTING MACHINES. Filed July 26, 1963. '7 Sheets-Sheet l. I I1. INVENTOR. JACQUES ...
Download Now - The Burrill Report
Jan 24, 2014 ... Jacques Bienaime as its new CEO in May 2005, the trou- bled biotech was reeling from a disastrous product acquisition, in the midst of a proxy ...
for the Treatment of Patients With Morquio A Syndrome
Nov 19, 2013 ... patients," said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. "I am very pleased with the outcome of today's panel vote and look ...
No data available

Faces(4)

 
 
No data available

Social networks(12)

 
No data available
No data available
No data available
 
No data available
No data available
No data available
No data available
No data available
No data available
Find hidden profiles and photos for Jacques Bienaime across MySpace, Facebook and 40+ networks.

Videos(24)

 
 
 
 

News(8)

No data available
BioMarin to Present at the Robert W. Baird Healthcare Conference
NOVATO, Calif., Sept. 8 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York City on Wednesday, September 15, 2010 at 10:30 a.m. ET. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call. About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release. BioMarin, Naglazyme and Kuvan are registered trademarks of BioMarin Pharmaceutical Inc. Firdapse is a trademark of BioMarin Huxley Ltd. Aldurazyme is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Eugenia Shen BioMarin Pharmaceutical Inc. (415) 506-6570 SOURCEBioMarin Pharmaceutical Inc. Back to top RELATED LINKS http://www.bmrn.com var js="0.0";js="1.0";js="1.1";js="1.2";js="1.3";js="1.4";js="1.5";js="1.6";js="1.7";js="1.8";js="1.9"; var flashvars = {}; var params = ; var attributes = {}; attributes.id = "PRNWPlayerFCID"; //swfobject.switchOffAutoHideShow(); swfobject.embedSWF("http://content.prnewswire.com/designvideo/PRNWPlayer.swf", "flashcontent", "200", "130", "9.0.0", "http://content.prnewswire.com/designvideo/expressInstall.swf", flashvars, params, attributes); function sendToFlash(strCmd, strData) { var objs = document.getElementById("PRNWPlayerFCID"); if (objs != null){ objs.player_ReceivFromJS(strCmd, strData); }else{ //alert("objs not created"); } } function player_SendToJS(strCmd, strData){ var multivuPlayer = document.getElementById("multivuPlayer"); if (strCmd == "URLOpen"){ window.open(strData); }else if (strCmd == "ShowTitle"){ var textDiv = document.getElementById("textcontent"); textDiv.appendChild(document.createTextNode(strData)); if(jQuery.trim(strData)==""){ multivuPlayer.style.display="none"; } } } Featured Video var trkcid=102428099;var partnerID=506122; var _hb=1; Share Print Email RSS Blog it WordPress Blog URL: Blog Search Other News Releases in Health Care & Hospitals Al's Angels' '24 Hours of Hope' Event to Support Children and Families in Desperate Need Misonix Announces New Distribution Agreement for France Lengthened Telomeres Restore Immune System to a Younger State Other News Releases in Trade Show News Ameren CFO to Present at Barclays Capital CEO Energy - Power Conference Business Kicks on Route 66: SAP Hits the Road in Chicago and California Digital Detectives Podcast on Legal Talk Network Features Judge David Waxse offering 'An Inside Look at the 2010 Civil Litigation Conference at Duke Law School' Journalists and Bloggers Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media. View and download archived video content distributed by MultiVu on The Digital Center. Newstogram.init('e58aac080a2606121e77aba437a3165d'); Newstogram.pageView();
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announces
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 30, at 5:00 p.m. ET (23:00 CET) to discuss first quarter 2009 financial results.
BMRN, CLNO, JDAS, NBTF - Market Watch From DoubleInStocks.com! | Double In Stocks
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Marketwire SOUTH SAN FRANCISCO, CA--(Marketwire - September 23, 2010) - Portola Pharmaceuticals, Inc. today announced the appointment of Jean-Jacques Bienaim tothe company's board of directors.Mr. Bienaim currently serves as chief executive officer of BioMarin Pharmaceutical Inc. He is chairman of the board of NeurogesX, Inc., a member of the board of BIO and a member of the advisory board of Bellevue Asset Management's BioVentures II fund. "Jean-Jacques Bienaim is a biotechnology and pharmaceutical industry veteran with more than 25 years of experience," said William Lis, chief executive officer of Portola."His experience as a CEO managing and building fully integrated biotechnology companies and his expertise commercializing anti-thrombotic products will be invaluable to Portola as we advance our two lead partnered product candidates, elinogrel and betrixaban, and our pipeline of proprietary products in cardiovascular disease and inflammation through clinical development and into commercialization." Mr. Bienaim joined BioMarin, which develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in May 2005 as chief executive officer and member of the board of directors.Prior to joining BioMarin, he served as chairman, chief executive officer and president of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Before that, he served as chairman, chief executive officer and president of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. Earlier in his career, Mr. Bienaim held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now sanofi-aventis) culminating in the position of senior vice president of worldwide marketing and business development responsible for, among other things, the launch of Lovenox (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States. He also worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. He received an M.B.A. from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the cole Suprieure de Commerce de Paris. About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have features to address the global multi-billion dollar hospital, specialty and chronic care anticoagulant and antiplatelet markets, respectively. Portola's proprietary pipeline programs are focused on the discovery and development of PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin; PRT064445, a Factor Xa inhibitor antidote to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade; and PRT062607, a novel, oral Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. For additional information, visit www.portola.com.
Portola Pharmaceuticals appoints Jean-Jacques Bienaime to board of directors
September 23, 2010, San Francisco, Ca., USA - Portola Pharmaceuticals, Inc., a biopharmaceutical company, announced the appointment of Jean-Jacques Bienaim to the company's board...
BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, ...
NOVATO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at 5:00 p.m. ET to discuss third quarter 2010 financial results. U.S. / Canada Dial-in Number: 866.202.3048 International Dial-in Number: 617.213.8843 Participant Code: 60493555 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number: 617.801.6888 Replay Code: 45911037 Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call. About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release. BioMarin, Naglazyme and Kuvan are registered trademarks of BioMarin Pharmaceutical Inc. Firdapse is a trademark of BioMarin Huxley Ltd. Aldurazyme is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Eugenia Shen BioMarin Pharmaceutical Inc. (415) 506-6570 SOURCEBioMarin Pharmaceutical Inc. Back to top RELATED LINKS http://www.bmrn.com var js="0.0";js="1.0";js="1.1";js="1.2";js="1.3";js="1.4";js="1.5";js="1.6";js="1.7";js="1.8";js="1.9"; var flashvars = {}; var params = ; var attributes = {}; attributes.id = "PRNWPlayerFCID"; //swfobject.switchOffAutoHideShow(); swfobject.embedSWF("http://content.prnewswire.com/designvideo/PRNWPlayer.swf", "flashcontent", "200", "130", "9.0.0", "http://content.prnewswire.com/designvideo/expressInstall.swf", flashvars, params, attributes); function sendToFlash(strCmd, strData) { var objs = document.getElementById("PRNWPlayerFCID"); if (objs != null){ objs.player_ReceivFromJS(strCmd, strData); }else{ //alert("objs not created"); } } function player_SendToJS(strCmd, strData){ var multivuPlayer = document.getElementById("multivuPlayer"); if (strCmd == "URLOpen"){ window.open(strData); }else if (strCmd == "ShowTitle"){ var textDiv = document.getElementById("textcontent"); textDiv.appendChild(document.createTextNode(strData)); if(jQuery.trim(strData)==""){ multivuPlayer.style.display="none"; } } } Featured Video var trkcid=104483334;var partnerID=506122; var _hb=1; Share Print Email RSS Blog it WordPress Blog URL: Blog Search Other News Releases in Biotechnology US Oncology to Report 2010 Third Quarter Operating Results Castle Access Names New Managing Director Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes Journalists and Bloggers Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media. View and download archived video content distributed by MultiVu on The Digital Center. Newstogram.init('e58aac080a2606121e77aba437a3165d'); Newstogram.pageView();
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares
CEO of BioMarin Pharmaceutical Inc. (BMRN) Jean Jacques Bienaime sells 1,000 shares of BMRN on 03/08/2012 at an average price of $35 a share. Biomarin Pharma has a market cap of $4.07 billion; its shares were traded at around $34.3602 with and P/S ratio of ...
Small biotechs raring to cash in on the orphan disease market
Looking ahead, “2012 is going to be an important year for BioMarin,” says chief executive Jean-Jacques Bienaime. “We are confident in our pipeline and look forward to significant milestones in the next year.” With a staff of around 130 ...
No data available
No data available
No data available
No data available
No data available

Related people(15)

Aime Bienaime Chicago IL 60659
Carline B Bienaime Miami FL 33238
Carline Bienaime Miami FL 33168
Carline Bienaime Queens Village NY 11428
Gracia Bienaime Opa Locka FL 33055
Henry Bienaime Uniondale NY 11553
Jacques Bienaime Roanoke VA 24019
Jacques B Bienaime Brooklyn NY 11226
Jacques Bienaime Pompano Beach FL 33064
Jacques Bienaime Pompano Beach FL 33064
Jean E Bienaime New York NY 10040
Jean Bienaime Naples FL 34102
Jean Bienaime Key West FL 33040
Jean P Bienaime Key West FL 33040
Jean P Bienaime Key West FL 33040

Microblogs(0)

 
Loading...
Loading...

Biography(10)

No data available
BioMarin Pharmaceutical
USA | location | locations | area_served | key_people Jean-Jacques Bienaime, Chief Executive Officer Henry J. Fuchs, Chief Medical ...
Carole Bienaimé
Carole Bienaimé (alter name Carole Bienaimé-Besse), is a French producer (TV and ... Unlimited marriage II by Jacques Audiard (Chrysalis ) ...
List of perfumes
Fleurs Houbigant | Robert Bienaimé | 1913 | April Violets Yardley | c. ... Must de Cartier Cartier | Jean-Jacques Diener | 1981 | Nombre ...
Asimov's Biographical Encyclopedia of Science and Technology
325 | Montgolfier, Jacques Etienne Andjoseph Michel | ... Entries include !: 493 | Caventou, Joseph Bienaime | 494 | Braid, James | ...
Prix de Rome
Jacques-Louis David , having failed to win the prize three years in a ... Winners in the Musical : 1826 – Claude Paris and Emile Bienaimé ...
Paul Antoine Bien-Aimé
He was appointed to the Cabinet by Jacques-Édouard Alexis on June 6 ... NAME Bien-Aime, Paul Antoine | ALTERNATIVE NAMES | SHORT DESCRIPTION ...
List of craters on the Moon, C–F
C ! : Jacques J. Cassini (1677–1756) | Catalán 25 km | Miguel A. Catalán (1894– ... Caventou 3 km | Joseph Bienaime Caventou (1795–1877) | ...
Allevard
the chemist Joseph Bienaimé Caventou ; the feminist Arria Ly who ... Niepce the Director of the Spa); the designer Jacques Faizant ; the ...
Javal family
Starting with the two Javal brothers (both named Jacques, and called ... In 1912, Houbigant perfumer Bienaimé picked up the ball from Paul ...
Pierre Jean Robiquet
In 1816, together with Jean-Jacques Colin they obtain a new component which they ... Associated articles : Joseph Bienaimé Caventou http://www. ...